LXRX Financial Statements

Balance sheet, income statement, cash flow, and dividends for Lexicon Pharmaceuticals Inc (LXRX).


$266.96M Market Cap.

As of 03/07/2025 5:00 PM ET (MRY) • Disclaimer

LXRX Market Cap. (MRY)


LXRX Shares Outstanding (MRY)


LXRX Assets (MRY)


Total Assets

$298.42M

Total Liabilities

$152.47M

Total Investments

$171.30M

LXRX Income (MRY)


Revenue

$31.08M

Net Income

-$200.40M

Operating Expense

$227.58M

LXRX Cash Flow (MRY)


CF Operations

-$178.78M

CF Investing

-$15.38M

CF Financing

$238.35M

LXRX Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

LXRX Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$298,420,000 (30.07%)

$229,429,000 (18.08%)

$194,299,000 (41.92%)

$136,909,000 (-32.82%)

Assets Current

$246,193,000 (39.45%)

$176,547,000 (25.33%)

$140,866,000 (58.42%)

$88,921,000 (-43.62%)

Assets Non-Current

$52,227,000 (-1.24%)

$52,882,000 (-1.03%)

$53,433,000 (11.35%)

$47,988,000 (4.17%)

Goodwill & Intangible Assets

$44,543,000 (0.00%)

$44,543,000 (0.00%)

$44,543,000 (0.00%)

$44,543,000 (0.00%)

Shareholders Equity

$145,950,000 (56.75%)

$93,110,000 (-20.50%)

$117,124,000 (3.11%)

$113,595,000 (-27.36%)

Property Plant & Equipment Net

$7,316,000 (-2.60%)

$7,511,000 (-11.41%)

$8,478,000 (146.10%)

$3,445,000 (1067.80%)

Cash & Equivalents

$66,656,000 (196.71%)

$22,465,000 (-51.53%)

$46,345,000 (-27.66%)

$64,065,000 (-49.26%)

Accumulated Other Comprehensive Income

$119,000 (283.87%)

$31,000 (107.24%)

-$428,000 (-4180.00%)

-$10,000 (-66.67%)

Deferred Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Investments

$171,301,000 (16.09%)

$147,561,000 (60.37%)

$92,012,000 (305.73%)

$22,678,000 (-12.82%)

Investments Current

$171,301,000 (16.09%)

$147,561,000 (60.37%)

$92,012,000 (305.73%)

$22,678,000 (-12.82%)

Investments Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Inventory

$231,000 (-39.37%)

$381,000 (0%)

$0 (0%)

$0 (0%)

Trade & Non-Trade Receivables

$3,473,000 (243.86%)

$1,010,000 (3507.14%)

$28,000 (100.00%)

$14,000 (-96.46%)

Trade & Non-Trade Payables

$14,801,000 (2.86%)

$14,389,000 (38.42%)

$10,395,000 (13.58%)

$9,152,000 (67.34%)

Accumulated Retained Earnings (Deficit)

-$1,967,242,000 (-11.34%)

-$1,766,839,000 (-11.14%)

-$1,589,720,000 (-6.85%)

-$1,487,776,000 (-6.27%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$100,298,000 (-4.27%)

$104,773,000 (94.01%)

$54,003,000 (4438.07%)

$1,190,000 (-89.78%)

Debt Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Debt Non-Current

$100,298,000 (-4.27%)

$104,773,000 (94.01%)

$54,003,000 (4438.07%)

$1,190,000 (0%)

Total Liabilities

$152,470,000 (11.85%)

$136,319,000 (76.64%)

$77,175,000 (231.02%)

$23,314,000 (-50.83%)

Liabilities Current

$45,248,000 (43.43%)

$31,546,000 (36.14%)

$23,172,000 (4.74%)

$22,124,000 (-52.73%)

Liabilities Non-Current

$107,222,000 (2.34%)

$104,773,000 (94.01%)

$54,003,000 (4438.07%)

$1,190,000 (94.76%)

LXRX Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$31,081,000 (2481.48%)

$1,204,000 (766.19%)

$139,000 (-53.36%)

$298,000 (-98.76%)

Cost of Revenue

$616,000 (624.71%)

$85,000 (0%)

$0 (0%)

$0 (0%)

Selling General & Administrative Expense

$143,102,000 (25.55%)

$113,982,000 (137.05%)

$48,083,000 (48.67%)

$32,342,000 (-31.52%)

Research & Development Expense

$84,480,000 (43.46%)

$58,887,000 (11.49%)

$52,816,000 (-4.05%)

$55,046,000 (-64.17%)

Operating Expenses

$227,582,000 (31.65%)

$172,869,000 (71.33%)

$100,899,000 (15.46%)

$87,388,000 (25.08%)

Interest Expense

$15,579,000 (18.91%)

$13,101,000 (371.26%)

$2,780,000 (246.63%)

$802,000 (-94.49%)

Income Tax Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$200,403,000 (-13.15%)

-$177,119,000 (-73.74%)

-$101,944,000 (-16.16%)

-$87,758,000 (-49.82%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$200,403,000 (-13.15%)

-$177,119,000 (-73.74%)

-$101,944,000 (-16.16%)

-$87,758,000 (-49.82%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$200,403,000 (-13.15%)

-$177,119,000 (-73.74%)

-$101,944,000 (-16.16%)

-$87,758,000 (-49.82%)

Weighted Average Shares

$320,031,000 (44.73%)

$221,130,000 (33.43%)

$165,733,000 (13.79%)

$145,652,000 (31.41%)

Weighted Average Shares Diluted

$320,031,000 (44.73%)

$221,130,000 (33.43%)

$165,733,000 (13.79%)

$145,652,000 (31.41%)

Earning Before Interest & Taxes (EBIT)

-$184,824,000 (-12.69%)

-$164,018,000 (-65.40%)

-$99,164,000 (-14.04%)

-$86,956,000 (-97.49%)

Gross Profit

$30,465,000 (2622.52%)

$1,119,000 (705.04%)

$139,000 (-53.36%)

$298,000 (-98.65%)

Operating Income

-$197,117,000 (-14.77%)

-$171,750,000 (-70.45%)

-$100,760,000 (-15.70%)

-$87,090,000 (-82.20%)

LXRX Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

-$15,378,000 (69.21%)

-$49,943,000 (29.73%)

-$71,078,000 (-3468.63%)

$2,110,000 (-99.45%)

Net Cash Flow from Financing

$238,349,000 (26.81%)

$187,960,000 (32.17%)

$142,209,000 (526.22%)

$22,709,000 (115.38%)

Net Cash Flow from Operations

-$178,780,000 (-10.43%)

-$161,897,000 (-82.21%)

-$88,851,000 (-2.11%)

-$87,017,000 (39.14%)

Net Cash Flow / Change in Cash & Cash Equivalents

$44,191,000 (285.05%)

-$23,880,000 (-34.76%)

-$17,720,000 (71.51%)

-$62,198,000 (-168.99%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

-$14,347,000 (71.00%)

-$49,473,000 (29.07%)

-$69,752,000 (-2194.03%)

$3,331,000 (-98.41%)

Capital Expenditure

-$1,031,000 (-119.36%)

-$470,000 (64.56%)

-$1,326,000 (-8.60%)

-$1,221,000 (-111.18%)

Issuance (Repayment) of Debt Securities

-$1,307,000 (-102.62%)

$49,961,000 (2.24%)

$48,868,000 (517.68%)

-$11,700,000 (94.60%)

Issuance (Purchase) of Equity Shares

-$1,666,000 (-101.21%)

$137,999,000 (47.84%)

$93,341,000 (171.27%)

$34,409,000 (-50.09%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$13,499,000 (-5.86%)

$14,340,000 (24.48%)

$11,520,000 (8.92%)

$10,577,000 (-20.32%)

Depreciation Amortization & Accretion

$534,000 (-3.61%)

$554,000 (29.74%)

$427,000 (46.23%)

$292,000 (-90.05%)

LXRX Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

98.00% (5.49%)

92.90% (-7.10%)

100.00% (0.00%)

100.00% (8.70%)

Profit Margin

-644.80% (95.62%)

-14710.90% (79.94%)

-73341.00% (-149.04%)

-29449.00% (-11964.32%)

EBITDA Margin

-592.90% (95.63%)

-13576.70% (80.89%)

-71033.80% (-144.25%)

-29081.90% (-16877.17%)

Return on Average Equity (ROAE)

-93.90% (32.78%)

-139.70% (-45.52%)

-96.00% (-47.69%)

-65.00% (20.05%)

Return on Average Assets (ROAA)

-56.80% (21.00%)

-71.90% (-11.82%)

-64.30% (-23.42%)

-52.10% (-138.99%)

Return on Sales (ROS)

-594.70% (95.63%)

-13622.80% (80.90%)

-71341.00% (-144.49%)

-29179.90% (-15801.85%)

Return on Invested Capital (ROIC)

-58.20% (20.82%)

-73.50% (33.72%)

-110.90% (80.77%)

-576.70% (-2375.11%)

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

-1.17 (38.73%)

-1.91 (37.91%)

-3.08 (53.08%)

-6.57 (-1.77%)

Price to Sales Ratio (P/S)

7.6 (-97.29%)

281 (-87.66%)

2,277.33 (18.26%)

1,925.74 (12089.75%)

Price to Book Ratio (P/B)

1.83 (-54.56%)

4.03 (30.77%)

3.08 (-40.40%)

5.16 (101.01%)

Debt to Equity Ratio (D/E)

1.04 (-28.62%)

1.46 (122.15%)

0.66 (221.46%)

0.2 (-32.34%)

Earnings Per Share (EPS)

-0.63 (21.25%)

-0.8 (-29.03%)

-0.62 (-3.33%)

-0.6 (-13.21%)

Sales Per Share (SPS)

0.1 (1840.00%)

0.01 (400.00%)

0 (-50.00%)

0 (-99.07%)

Free Cash Flow Per Share (FCFPS)

-0.56 (23.43%)

-0.73 (-34.93%)

-0.54 (10.23%)

-0.61 (49.12%)

Book Value Per Share (BVPS)

0.46 (8.31%)

0.42 (-40.45%)

0.71 (-9.36%)

0.78 (-44.72%)

Tangible Assets Book Value Per Share (TABVPS)

0.79 (-5.14%)

0.84 (-7.52%)

0.9 (42.59%)

0.63 (-55.88%)

Enterprise Value Over EBIT (EV/EBIT)

-2 (33.33%)

-3 (25.00%)

-4 (33.33%)

-6 (25.00%)

Enterprise Value Over EBITDA (EV/EBITDA)

-1.8 (35.70%)

-2.8 (24.24%)

-3.7 (36.64%)

-5.84 (35.09%)

Asset Turnover

0.09 (1660.00%)

0.01 (400.00%)

0 (-50.00%)

0 (-97.75%)

Current Ratio

5.44 (-2.77%)

5.6 (-7.95%)

6.08 (51.26%)

4.02 (19.26%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$179,811,000 (-10.74%)

-$162,367,000 (-80.05%)

-$90,177,000 (-2.20%)

-$88,238,000 (33.17%)

Enterprise Value (EV)

$332,306,060 (-27.50%)

$458,326,783 (25.43%)

$365,416,169 (-27.82%)

$506,224,086 (36.88%)

Earnings Before Tax (EBT)

-$200,403,000 (-13.15%)

-$177,119,000 (-73.74%)

-$101,944,000 (-16.16%)

-$87,758,000 (-49.82%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$184,290,000 (-12.74%)

-$163,464,000 (-65.55%)

-$98,737,000 (-13.93%)

-$86,664,000 (-110.88%)

Invested Capital

$242,271,000 (2.81%)

$235,648,000 (75.54%)

$134,242,000 (1722.21%)

$7,367,000 (438.25%)

Working Capital

$200,945,000 (38.58%)

$145,001,000 (23.20%)

$117,694,000 (76.20%)

$66,797,000 (-39.78%)

Tangible Asset Value

$253,877,000 (37.32%)

$184,886,000 (23.46%)

$149,756,000 (62.13%)

$92,366,000 (-42.00%)

Market Capitalization

$266,962,060 (-28.76%)

$374,734,783 (3.96%)

$360,466,169 (-38.56%)

$586,649,086 (46.02%)

Average Equity

$213,327,250 (68.30%)

$126,756,750 (19.39%)

$106,167,500 (-21.35%)

$134,994,500 (87.43%)

Average Assets

$352,529,500 (43.11%)

$246,337,000 (55.30%)

$158,621,750 (-5.89%)

$168,542,750 (-37.33%)

Invested Capital Average

$317,676,000 (42.28%)

$223,267,500 (149.69%)

$89,419,250 (493.02%)

$15,078,750 (-92.04%)

Shares

361,492,295 (47.59%)

244,924,695 (29.78%)

188,725,743 (26.75%)

148,895,707 (26.75%)